Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Children's Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Phase 2

Completed

Conditions: Recurrent Ewing Sarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Childhood Soft Tissue Sarcoma
Peripheral Primitive Neuroectodermal Tumor

Interventions: Drug: trabectedin
Other: pharmacological study

First Posted Date: 2003-10-07

Last Posted Date: 2018-09-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 50

Registration Number: NCT00070109

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
Childrens Memorial Hospital, Chicago, Illinois, United States

and more 11 locations

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: gemcitabine hydrochloride
Drug: vinorelbine tartrate

First Posted Date: 2003-10-07

Last Posted Date: 2013-07-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 33

Registration Number: NCT00070304

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Southern California Permanente Medical Group, Downey, California, United States

and more 120 locations

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

Phase 2

Completed

Conditions: Desmoid Tumor

Interventions: Drug: tamoxifen citrate
Drug: sulindac
Other: laboratory biomarker analysis

First Posted Date: 2003-09-11

Last Posted Date: 2020-02-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 70

Registration Number: NCT00068419

Locations: 🇺🇸
Children's Oncology Group, Monrovia, California, United States

Interferon Alfa in Treating Children With HIV-Related Cancer

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Lymphoma
Leukemia

Interventions: Biological: recombinant interferon alfa

First Posted Date: 2003-08-11

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 8

Registration Number: NCT00002621

Locations: 🇺🇸
Via Christi Regional Medical Center, Wichita, Kansas, United States
🇺🇸
MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States
🇺🇸
Tomorrows Children's Institute, Hackensack, New Jersey, United States

and more 7 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Not Applicable

Completed

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Procedure: conventional surgery
Biological: MESNA

First Posted Date: 2003-08-07

Last Posted Date: 2013-10-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 19

Registration Number: NCT00066482

Locations: 🇺🇸
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 95 locations

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Phase 2

Completed

Conditions: Sarcoma
Metastatic Cancer

Interventions: Biological: sargramostim
Procedure: conventional surgery

First Posted Date: 2003-08-07

Last Posted Date: 2015-03-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 49

Registration Number: NCT00066365

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

and more 90 locations

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Phase 2

Completed

Conditions: Lymphoproliferative Disorder

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: methylprednisolone
Drug: prednisone

First Posted Date: 2003-08-07

Last Posted Date: 2019-08-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 55

Registration Number: NCT00066469

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 75 locations

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: vinblastine sulfate
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy
Drug: MESNA
Drug: Filgrastim

First Posted Date: 2003-06-06

Last Posted Date: 2019-02-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 38

Registration Number: NCT00061893

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 98 locations

Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-06-05

Last Posted Date: 2014-05-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 7

Registration Number: NCT00008424

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
University of California San Diego Cancer Center, La Jolla, California, United States

and more 48 locations

Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: irinotecan hydrochloride
Drug: vincristine sulfate

First Posted Date: 2003-05-22

Last Posted Date: 2014-02-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT00006095

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy